Daniel Roberts, MD
Nephrology · Portland, ORNPI 1205248523
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $555 of the $769 with a category attached, or 72.2%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.0%. 2025 is the largest year on record at $404, 2.1 times the $189 reported in 2019.
Across 29 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$161
- Sanofi-aventis U.S. LLC$99
- Mallinckrodt Enterprises LLC$90
- Travere Therapeutics, Inc.$58
- Vifor Pharma, Inc.$50
- Calliditas Therapeutics US Inc.$46
- plus $265 from 9 others
What the payments were for
- Travel & lodging$213%
- Food & beverage$55572%
- Education$19325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $161 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Mallinckrodt Enterprises LLC | 1 | $90 |
| Travere Therapeutics, Inc. | 4 | $58 |
| Vifor Pharma, Inc. | 2 | $50 |
| Calliditas Therapeutics US Inc. | 1 | $46 |
| Boehringer Ingelheim | 2 | $44 |
| Amgen(2 entities) | 2 | $42 |
| AstraZeneca | 2 | $40 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Novartis | 1 | $31 |
| GSK | 2 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $14 |
| Veloxis Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$769 in reported general payments places this provider in the 80th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $51,724 |
| FarxigaDapagliflozin Propanediol | 36 | $30,157 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $19,610 |
| Sevelamer Carbonate | 29 | $7,407 |
| Potassium Citrate ErPotassium Citrate | 32 | $3,427 |
| Midodrine Hcl | 29 | $1,123 |
| Losartan Potassium | 66 | $795 |
| Amlodipine Besylate | 67 | $658 |
| Spironolactone | 36 | $623 |
| Hydralazine Hcl | 30 | $521 |
| Torsemide | 20 | $474 |
| Carvedilol | 57 | $462 |
| Chlorthalidone | 24 | $424 |
| Furosemide | 65 | $391 |
| Lisinopril | 51 | $345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $44 | $51,72442 claims |
| AstraZenecaFarxiga | $40 | $30,15736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 nephrology providers in Oregon.
Other nephrology in Portland
- Robert ProvenzanoPortland$45K
- Nayan AroraPortland$23K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Arthur GreenbergPortland$7K
- Suzanne WatnickPortland$2K
- Hem DeodharPortland$1K
- Julia TankPortland$1K
- Chun Khai ChongPortland$956
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.